Castle Biosciences Inc (FRA:086) Stock Price, Trades & News

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	7.13
Equity-to-Asset	0.84
Debt-to-Equity	0.08
Debt-to-EBITDA	-14.59
Piotroski F-Score	2/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	5.6	Distress Grey Safe
Beneish M-Score	-3.04	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	31.2
	3-Year EPS without NRI Growth Rate	65
	3-Year Book Growth Rate	1.8
	Future 3-5Y Total Revenue Growth Rate Estimate	8.46

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	63.97
	9-Day RSI	67.04
	14-Day RSI	63.62
	3-1 Month Momentum %	-26.67
	6-1 Month Momentum %	-30.63

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	6.75
	Quick Ratio	6.53
	Cash Ratio	5.37
	Days Inventory	43.29
	Days Sales Outstanding	52.36
	Days Payable	65.68

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-3.8
	Shareholder Yield %	-1.5

Profitability Rank

3/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	77.88
	Operating Margin %	-9.79
	Net Margin %	-3.78
	EBITDA Margin %	-0.74
	FCF Margin %	1.24
	OCF Margin %	14.1
	ROE %	-2.8
	ROA %	-2.35
	ROIC %	-9.74
	3-Year ROIIC %	68.02
	ROC (Joel Greenblatt) %	-14.89
	ROCE %	-3.53
	Years of Profitability over Past 10-Year	2
	Moat Score	6
	Tariff Resilience Score	7

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	2.09
	PB Ratio	1.58
	Price-to-Tangible-Book	2.01
	Price-to-Free-Cash-Flow	137.77
	Price-to-Operating-Cash-Flow	14.52
	EV-to-EBIT	-29.01
	EV-to-Forward-EBIT	-9.83
	EV-to-EBITDA	-201.15
	EV-to-Revenue	1.49
	EV-to-Forward-Revenue	1.43
	EV-to-FCF	112.06
	Price-to-GF-Value	0.85
	Price-to-Projected-FCF	2.98
	Price-to-Net-Current-Asset-Value	3.01
	Price-to-Net-Cash	4.16
	Earnings Yield (Greenblatt) %	-3.45
	FCF Yield %	0.62

Financials (Next Earnings Date:2026-08-04 Est.)

Annual Quarterly TTM

FRA:086's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Castle Biosciences Inc Executives

Details

GF Value™: €24.1

FRA:086

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with 086. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	292.167
	EPS (TTM) (€)	-0.379
	Beta	-
	3-Year Sharpe Ratio	-
	3-Year Sortino Ratio	-
	Volatility %	-
	14-Day RSI	63.62
	14-Day ATR (€)	0.560671
	20-Day SMA (€)	18.535
	12-1 Month Momentum %	-
	52-Week Range (€)	15.2 - 35.6
	Shares Outstanding (Mil)	30.33

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	2
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Castle Biosciences Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Castle Biosciences Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-03 16:30	In 121 days
Third quarter earnings results for 2026	2026-11-03	In 120 days
Second quarter earnings conference call for 2026	2026-08-04 16:30	In 30 days
Second quarter earnings results for 2026	2026-08-04	In 29 days
Guidance call for 2026	2026-06-03 13:20	17.60 (+0.00%)
General meeting for 2026	2026-05-28 10:00	16.60 (+0.00%)
First quarter earnings conference call for 2026	2026-05-06 16:30	21.60 (+0.93%)
First quarter earnings results for 2026	2026-05-06	21.60 (+0.93%)
Fourth quarter earnings conference call for 2025	2026-02-26 16:30	25.20 (+1.61%)
Annual report for 2025	2026-02-26	25.20 (+1.61%)

Show

Entries

Castle Biosciences Inc Frequently Asked Questions

What is Castle Biosciences Inc(FRA:086)'s stock price today?

The current price of FRA:086 is €20.60. The 52 week high of FRA:086 is €35.60 and 52 week low is €15.20.

When is next earnings date of Castle Biosciences Inc(FRA:086)?

The next earnings date of Castle Biosciences Inc(FRA:086) is 2026-08-04 Est..

Does Castle Biosciences Inc(FRA:086) pay dividends? If so, how much?

Castle Biosciences Inc(FRA:086) does not pay dividend.

Press Release

	Subject	Date
	DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy	2026-06-25
	Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal	2026-06-23
	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	2026-06-19
	Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus	2026-06-16
	Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference	2026-05-13
	Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation	2026-05-12
	Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS	2026-04-21
	Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026	2026-04-15
	Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year	2026-04-10
	New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio	2025-03-07

10/Page

Articles on Castle Biosciences Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.